Sarepta Therapeutics (SRPT) Tops Q2 EPS by 20c

Go back to Sarepta Therapeutics (SRPT) Tops Q2 EPS by 20c

Sarepta Therapeutic (SRPT) PT Bumped to $35 at RBC Capital

August 7, 2015 8:21 AM EDT

RBC Capital analyst Simos Simeonidis reiterated a Sector Perform rating and boosted his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $35.00 (from $20.00) to account for the potential value of eteplirsen's follow-on exon programs.

Simeonidis commented, "Sarepta updated investors on the progress of... More

Sarepta Therapeutic (SRPT) PT Raised to $47 at Baird; Increasingly Bullish on Risk/Reward

August 7, 2015 7:41 AM EDT

Baird analyst Brian Skorney reiterated an Outperform rating and boosted his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $47.00 (from $34.00), saying they are increasingly bullish on risk/reward.

Sarepta commented, "After spending time with management recently and hearing additional granularity on the... More

SunTrust Downgrades Sarepta Therapeutic (SRPT) to Neutral

August 7, 2015 7:07 AM EDT

SunTrust Robinson Humphrey downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Buy to Neutral with a price target of $33 (unchanged).

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $34.63 yesterday.

... More